LifeMine Therapeutics
Develops fungal genome-derived therapeutics for organ transplant rejection
$263MSeries D+Series E
Role not disclosedLoading investors…
Loading investors…
Activity from announced rounds
Develops fungal genome-derived therapeutics for organ transplant rejection
Builds quantum computers using lasers to hold individual atoms in place
Develops bispecific antibody therapies for retinal vascular diseases including diabetic macular edema and wet AMD
Develops ultrasound-mediated nonviral genetic medicines
Develops next-generation RNAi therapeutics and engineering platform for multiple disease areas
Develops single-molecule PCR technology for genomics measurement
Develops in vivo immune programming platform for scalable, repeat-dose immunotherapies
Decodes cellular networks to advance human health
Develops functional single-cell analysis tools and platforms for life science research
Develops next-generation therapies for immune-mediated inflammatory and fibrotic diseases
Builds technologies for spatial biology and multi-omics innovation
Develops medicines targeting historically undruggable protein targets in cancer